The MBP CDA will be hosting a career webinar featuring MBP alumnus Zubin Master. The webinar will be hosted on August 5th, 2021 from 4-5 PM EST on Zoom.  Please register below to attend. A link will be emailed to you shortly before the webinar.

*****
Dr. Master's biography:
Dr. Zubin Master is an Associate Professor at Mayo Clinic’s Biomedical Ethics Research Program and the Center for Regenerative Medicine. Previously, he was an Associate Professor at the Alden March Bioethics Institute of Albany Medical College, Research Associate for University of Alberta’s Health Law Institute, and has held several adjunct or visiting professor appointments at the University of Montreal, the National Institute of Environmental Health Sciences (NIH), and the Ottawa Hospital Research Institute. Dr. Master also worked in public service as a Senior Policy Advisor at Health Canada where he led the development of Health Canada’s Scientific Integrity Framework and developed regulations under Canada’s Assisted Human Reproduction Act. He holds an undergraduate degree in genetics from York University, a PhD in cellular and molecular biology from the Department of Medical Biophysics from the University of Toronto, and a certificate in clinical ethics consultation from Albany Medical College. He completed post-doctoral fellowships in bioethics and health policy at Dalhousie University and the University of British Columbia. Dr. Master serves on several scientific committees, including the International Society for Stem Cell Research’s Education Committee and is ex-officio for the Public Policy Committee. He is also an Associate Editor for the journal Accountability in Research and has previously held various other editorial positions.

Dr. Master’s research interests broadly cover the ethical and policy issues related to stem cells and regenerative medicine, genetics, research ethics, and the responsible conduct of research. Dr. Master is interested in understanding how the beliefs and perceptions of patients are influenced by misinformation and what strategies may be employed to correct misinformation. His current work centers on health care decision-making in the context of the unregulated stem cell treatment marketplace. He is also interested in ethical and policy issues related to Right to Try and the FDA’s Expanded Access Program.